Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

Novartis

Status and phase: Terminated; Phase 2

Conditions: Diabetic Gastropathy

Treatments: Drug: Tegaserod

Study type: Interventional

Funder types: Industry

Identifiers

NCT00142974

CHTF919G2203

Details and patient eligibility

About

This study is being done to evaluate the safety, tolerability and satisfactory relief of tegaserod against dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years
• GI symptoms for at least 2 months before entering study

Exclusion criteria

• Very high body weight
• Significant diarrhea
• Ulcers

Symptom severity score collected via diary Other protocol-defined inclusion/exclusion criteria may apply.